Citation: Kahn JG, Marseille E, Auvert B (2007) Circumcision for HIV Prevention: Authors' Reply. PLoS Med 4(3): e146. https://doi.org/10.1371/journal.pmed.0040146
Published: March 27, 2007
Copyright: © 2007 Kahn et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors received no specific funding for this article.
Competing interests: The authors have declared that no competing interests exist.
The issues regarding risk compensation raised by Kalichman et al.  are cogent for refining modeled estimates of the impact of male circumcision (MC). Even more important is to empirically monitor risk compensation during the scale-up of male circumcision.
As Kalichman et al. note, we included in our modeling of MC impact a risk compensation level for men susceptible to HIV above that observed in the Orange Farm trial.
However, we did not incorporate risk compensation among the HIV infected, an adjustment which would have lessened the estimated benefits of male circumcision. These two biases are offsetting. Another conservative bias in our analysis is that we used the per-randomization protective effect of 0.60, rather than the per-clinical protocol protective effect of 0.70. Arguably, effectiveness in practice is better captured by the latter, and this would increase the estimated benefits of male circumcision.
The inclusion of the effects of non-HIV sexually transmitted infections (STIs) as risk co-factors would add a useful dimension to our analysis. The net effect could be to decrease or increase MC impact. As Kalichman et al. note, increased STIs associated with risk compensation in newly circumcised HIV-infected men would likely lessen MC impact. However, in a concentrated epidemic setting where STIs play a greater role in HIV transmission than in South Africa, the STI-reducing effects of MC in HIV-susceptible men could further increase the benefits of MC in preventing HIV.
Regarding the magnitude of risk compensation, we are encouraged by recent data suggesting that MC does not increase risky behavior, and may lead to a transient decrease . However, we, like Kalichman et al. and others, are eager to see the favorable experience in clinical trials carried over to routine and widely operating programs. Thus, the current efforts to plan MC scale-up emphasize the need for an MC procedure that incorporates effective risk reduction counseling. In the context of a medicalized adult male circumcision model, and a clear public health message, risk compensation can be minimized. Thus, a great value of MC scale-up is the opportunity to directly deliver a strong behavioral prevention message. A similar risk reduction message has worked well with antiretroviral therapy in Africa .
The ultimate and critical test is monitoring risk behaviors in communities where MC is scaled up. If risk compensation is higher than expected, redoubled risk reduction methods will be imperative.
- 1. Kalichman S, Eaton L, Pinkerton S (2007) Circumcision for HIV prevention: Failure to fully account for behavioral risk compensation. PLoS Med 4: e138.
- 2. Agot KE, Kiarie JN, Nguyen HQ, Odhiambo JO, Onyango TM, et al. (2007) Male circumcision in Siaya and Bondo Districts, Kenya: Prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 44: 66–70.
- 3. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, et al. (2006) Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 20: 85–92.